Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

By Chang Gee-Chen   Chen Kun-Chieh   Yang Tsung-Ying   Yin Ming-Chang   Lin Ching-Pei   Kuo Benjamin Ing-Tiau   Hsu Jeng-Yuan  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 73-77

Springer Publishing Company

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Erlotinib may be an effective therapy for elderly patients with advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

By Sugiura Takahiko   Ariyoshi Yutaka   Negoro Shunichi   Nakamura Shinichiro   Ikegami Harumichi   Takada Minoru   Yana Takashi   Fukuoka Masahiro  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 331-337

Springer Publishing Company

Access to resources Recommend Favorite